Clinical Trials Logo

Toxoplasmosis, Cerebral clinical trials

View clinical trials related to Toxoplasmosis, Cerebral.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04341155 Recruiting - Clinical trials for Toxoplasmosis, Cerebral

Dexamethasone for Cerebral Toxoplasmosis

De-Tox
Start date: April 16, 2021
Phase: Phase 2
Study type: Interventional

Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.